Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies
1. 请及时下载文件确认是否正确, 系统将在 2025-06-23 15:32:22 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/s0140-6736(25)00825-6
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0140673625008256
其他信息:
出版社: Elsevier BV
作者: Beryl B Cummings; Mark P Joing; Page R Bouchard; Mark N Milton; Peter F Moesta; Vyas Ramanan; Andrew Lane; Joe Hirman; John W Trauger; Eleftheria Maratos-Flier; Andrei Voznesensky; Igor Splawski; Amitabh V Nimonkar; Meghan M Flaherty; B Alexander Yi; Daniel Meyers; Francois Huet; Sukhdeep K Sahambi; Denise P Yates; Douglas Hom; Markus Hinder; Craig T Basson; Chris O'Donnell; Evan S Siegelman; Chris E Garrett; Joshua Lehrer-Graiwer; Rebecca A Juliano; Ethan J Weiss
